Intended use. Critical functions. Enough evidence for every release.

Computer system assurance should answer a precise question: for this version of this regulated system, do the controls and evidence give enough confidence that every critical function performs as intended?

That question is obscured when validation is organized around document names. An inventory sits in one spreadsheet, requirements in another, supplier evidence in a portal, tests in PDFs, configuration in tickets, and release approval in email. The packet may look complete while the actual production configuration has already moved.

Function-level computer system assurance

Risk determines the evidence needed for the actual production configuration; a document checklist does not.

Use

The regulated potency decision draws the assurance boundary.

Risk

Calculation failure receives deeper evidence than noncritical display behavior.

Evidence

Supplier, exploratory and automated evidence remain claim-specific.

Release

The accepted anomaly and deployed baseline remain frozen together.

A system record defines product, service model, owner, process owners, supplier, hosting, interfaces, data, users, locations, intended use, GxP rationale, electronic records and signatures, privacy and security dependencies, and lifecycle state.

Inventory is not a list of application names. Separate instances, tenants, modules, configurations, and uses can carry different risk and evidence even when supplied by the same vendor.

Intended use states which regulated decisions the system supports, the users and operating context, the records it creates, and the limits outside which it is not relied upon. Claims remain versioned and approved.

The boundary prevents two common failures: validating every product feature as if it were GxP-critical, and overlooking a small configured function that directly controls product quality or data integrity.

Risk is assessed at the level where harm occurs. A function connects its intended behavior, failure modes, process controls, detectability, patient or product impact, data-integrity impact, and existing safeguards.

Classification determines the depth and independence of assurance activity. It does not mechanically assign a fixed document set. The FDA's final Computer Software Assurance guidance emphasizes a risk-based approach and objective evidence appropriate to the software feature, function, or operation.

Supplier development controls, quality certification, architecture, security, testing, release notes, service history, availability, data recovery, incident response, change notification, and audit evidence can reduce duplicated work when their relevance and trust are assessed.

Seal records which claim each supplier artifact supports, its scope and version, who evaluated it, identified gaps, compensating work, and expiry or re-evaluation trigger. A SOC report in a folder is not automatically validation evidence.

Critical controls need explicit expected behavior. Lower-risk workflow, usability, and exploratory concerns may be described through intended use, configuration, acceptance criteria, or charters instead of inflated requirement catalogs.

Every requirement or control links forward to configuration and evidence and backward to its rationale. Orphan requirements and tests become visible rather than being hidden inside a trace matrix exported at the end.

Roles, permissions, workflows, fields, calculations, reports, integrations, master data, retention rules, signatures, audit trails, and environment settings form a governed configuration baseline.

The released state records what actually runs in production. A test performed against a different tenant, feature flag, interface mapping, or configuration version cannot silently qualify it.

Assurance can combine supplier evidence, automated checks, scripted tests, limited scripted tests, unscripted scenario testing, exploratory testing, inspection, analysis, monitoring, and production controls.

The strategy states why each technique is appropriate to the function and risk. Human-readable evidence can be concise, but it must still identify the tester, environment, date, activity, result, and observed failure where applicable.

An exploratory charter defines mission, scope, risks, data, personas, timebox, constraints, and evidence expectations. The execution captures notes, observations, screenshots or recordings where useful, anomalies, and tester conclusion.

Unscripted does not mean undocumented. It replaces prescriptive keystrokes with skilled investigation where that produces stronger evidence.

Environment identity, build, configuration, interfaces, data set, accounts, permissions, clock, and prerequisite state accompany every execution. Personally identifiable, patient, or production data use remains controlled.

Failed prerequisites and environment drift are visible. A passing test cannot be carried forward if the evidence cannot be tied to the relevant state.

Each unexpected result connects to the function, execution, evidence, severity, product or data impact, investigation, correction, retest, residual risk, and disposition. Known defects from the supplier enter the same decision surface.

Acceptance can include a documented limitation and compensating control, but only when its operational ownership and monitoring are explicit.

The release assembles intended use, current risk, supplier assessment, requirements and controls, configuration, testing, unresolved anomalies, procedures, training, continuity, migration, and operational readiness.

Approval freezes the accepted versions and rationale. Deployment confirmation proves the production state matches the released baseline before regulated use begins.

A supplier release, configuration update, integration mapping, role change, infrastructure event, procedure revision, or new intended use identifies affected functions, risks, evidence, records, and downstream controls.

The impact assessment recommends reuse, focused regression, new testing, procedure or training action, or full requalification. It also records why unaffected evidence remains valid.

Cloud systems may change more frequently than traditional validation projects. Service model, tenant controls, feature enablement, supplier notification, sandbox availability, deployment windows, rollback, and monitoring define the release policy.

Release-by-release evidence remains connected without recreating a complete validation plan from scratch. Emergency changes have a controlled path and retrospective obligations.

Service interruption, incorrect behavior, access issue, integration failure, data loss, audit-trail concern, or security event can challenge intended use. The incident identifies affected functions, records, time range, workaround, patient or product impact, and validation follow-up.

Recurring failures raise function risk and change the next test strategy. Production experience becomes lifecycle evidence instead of living outside validation.

Review evaluates intended-use changes, releases, configuration, users and access, incidents, deviations, audit trails, backup and restore, continuity tests, supplier performance, procedures, training, open risks, and retirement readiness.

The result can continue, conditionally continue, remediate, revalidate, restrict, replace, or retire the system. It is not a ceremonial rereading of the original validation summary.

Decommissioning maps records, metadata, audit trails, signatures, retention, legal holds, exports, readable rendering, migration verification, access, infrastructure removal, contracts, and destruction.

Seal separates retiring the application from retiring the obligation to preserve and retrieve its records.

Seal is strongest where system lifecycle and quality evidence meet: the actual production configuration, the functions that matter, the evidence relied upon, and the changes that challenge it. It can govern assurance for Seal itself and for laboratory, manufacturing, quality, clinical, infrastructure, and supplier systems around it.

The result is less ritual and more control: reviewers can see why the system is trusted today, not only that a packet was approved years ago.

The first implementation should follow one configured cloud system through inventory, intended use, critical-function assessment, supplier review, requirements, baseline, risk-based strategy, scripted and exploratory execution, anomaly, release, production verification, supplier update, focused regression, incident, periodic review, and retirement planning.

Include a supplier test reused with justification, a feature excluded from GxP scope, a high-risk calculation, role-permission failure, configuration drift between test and production, an accepted known defect with compensating control, a late release note, and an emergency patch. The first usable release must show exactly what was trusted, what remains uncertain, and why the current production state is authorized.